Portola Pharmaceuticals announced that the European Commission, or EC, has granted conditional Marketing Authorization for Ondexxya. “Ondexxya is the first and only antidote approved in Europe for adult patients treated with the Factor Xa inhibitor apixaban or rivaroxaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding,” the company said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.